Infliximab treatment in Psoriatic Arthritis: our experience

Infliximab treatment in Psoriatic Arthritis: our experience

Authors

  • W. Troise Rioda
  • G. Adorni

Keywords:

Psoriatic arthritis, cutaneous psoriasis, TNF-a, TNF-a blocking agents, Infliximab

Abstract

The aim of this work was to give clinical practice recommendations on the use of tumour necrosis factor blocking agents in psoriatic arthritis, underlining the pathogenetic mechanism of this condition and its articular and dermatologic manifestations.We retrace the stages leading to the therapeutic indications of biological agents that are presently used in the treatment of psoriatic arthritis: Entanercept,Adalimumab, Infliximab. We also report our personal experience describing an emblematic case of a patient with psoriatic arthritis in which a decisive regression of joint/skin involvement was obtained with Infliximab treatment.

Downloads

Published

01-08-2006

Issue

Vol. 77 No. 2 (2006)

Section

ORIGINAL ARTICLES

License

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. 
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

How to Cite

1.
Troise Rioda W, Adorni G. Infliximab treatment in Psoriatic Arthritis: our experience. Acta Biomed [Internet]. 2006 Aug. 1 [cited 2024 Jul. 28];77(2):95-102. Available from: https://mattioli1885journals.com/index.php/actabiomedica/article/view/1993